Nelson, Van Denburg & Campbell Wealth Management »

Arrivent Biopharma shares owned by Nelson, Van Denburg & Campbell Wealth Management

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Nelson, Van Denburg & Campbell Wealth Management from 13F filings

Historical chart of Nelson, Van Denburg & Campbell Wealth Management investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Nelson, Van Denburg & Campbell Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Nelson, Van Denburg & Campbell Wealth Management

Quarter filed Position value Share count Share price at filing
2024-12-31 $27k 996 26.64
2024-09-30 $21k 888 23.50
2024-06-30 $7.2k 390 18.55

More positions owned by Nelson, Van Denburg & Campbell Wealth Management

Vanguard Growth Etf Etf (VUG)
Ishares Core Dividend Growth Etf Etf (DGRO)
Vanguard Mid Cap Growth Etf Etf (VOT)
Vanguard Index Fds Mid-cap Value Index Viper Shs Etf Etf (VOE)
Ishares S&p 500 Index Etf (IVV)
Jpmorgan Active Value Etf Etf (JAVA)
Berkshire Hathaway Inc Del Cl B Stock (BRK.B)
Jpmorgan Active Growth Etf Etf (JGRO)
Apple Stock (AAPL)
Ishares Morningstar Mid-cap Growth Etf Etf (IMCG)
Invesco Bulletshares 2029 Corporate Bond Etf Etf (BSCT)
Invesco Bulletshares 2027 Corporate Bond Etf Etf (BSCR)
Vanguard Total Bond Market Etf Etf (BND)
Vanguard S&p 500 Etf Etf (VOO)
Vanguard Small Cap Growth Etf Etf (VBK)

View all positions for Nelson, Van Denburg & Campbell Wealth Management

Top funds holding Arrivent Biopharma

Hillhouse Capital Advisors
OrbiMed Advisors
Suvretta Capital Management
BlackRock
FMR
Octagon Capital Advisors
Sofinnova Ventures
Infinitum Asset Management
Novo A/S
General Catalyst Group Management
Vanguard Group
State Street Corporation
Sc China Holding
Geode Capital Management
Cormorant Asset Management

View all funds holding Arrivent Biopharma